Vestibular migraine in children and adolescents calls for an age-appropriate, stepwise management strategy. Evidence-based guidelines distinguish between younger children and adolescents 12 years and older, particularly when initial therapy does not provide adequate relief.

Clinical scenario

This protocol addresses vestibular migraine occurring in patients younger than 18 years. The recommended approach is structured around the patient's age and their response to first-line analgesic treatment.

Treatment approach (partial overview)

For adolescents 12 years and older who do not respond adequately to analgesics, agents within the triptan class are supported by sufficient clinical evidence and form part of the recommended regimen. The complete set of options, formulations, and the full evidence-based algorithm is available in the structured protocol.

References

DOI: 10.1177/2514183X1882337

Migraine attacks in children are treated with ibuprofen 10 mg/kg body weight (BW), ASA (500 mg) or paracetamol 15 mg/kg BW (second choice).
Sumatriptan 10 mg and zolmitriptan 5 mg as nasal spray are approved for the treatment of migraine in adolescents age 12 or older.
Sufficient data are available to justify the use of triptans (sumatriptan 10–20 mg as nasal spray, zolmitriptan 2.5–5 mg tablets, rizatriptan 5–10 mg tablets and almotriptan 12.5 mg tablets) in adolescents in case of inadequate response to acute therapy with analgesics.

View source ↗

What Is the Treatment of Vestibular Migraine in Patients Under 18 Years?

References